Monday, June 8

9:00am-12:00pm

Recommended Pre-Conference Short Course
(SC3) AVOIDING PITFALLS IN ALZHEIMER’S CLINICAL TRIAL DESIGN

AMYLOID APPROACHES

Genotype-Specific Therapeutic Responses in Alzheimer’s Disease
Lauren Costantini, Ph.D., Vice President, Clinical Development, Accera, Inc.

Therapeutics Based on Thalidomide
Prasad Gabbita, Vice President, Preclinical Development, P2D Biosciences

Blocking RTN3 Aggregation as a Therapeutic Target of Alzheimer’s Treatment
Riqiang Yan, Ph.D., Associate Professor, Neurosciences, Cleveland Clinic Lerner Research Institute

TAU APPROACHES

Phase II Proof of Concept: Update on Progress
Speaker to be Announced, TauRx Therapeutics, Ltd.

NEW AND EMERGING TARGETS

Novel Therapeutic Approaches Based on APP Signaling
Varghese John, Ph.D., Director, Alzheimer’s Drug Discovery Network, The Buck Institute

Apolipoprotein-E Mimetics Increase PP2a and Reduce Alzheimer’s Pathology
Michael Vitek, Ph.D., Chief Executive Officer, Neurology and Neuroscience, Cognosci, Inc.

TNF Modulation for Treatment of Alzheimer’s Disease
Edward Tobinick, M.D., Director, Medicine, Institute for Neurological Research, a Private Medical Group, Inc.